Jump to content
RemedySpot.com

Pharmasset Announces 91% SVR12 from the Proton Trial in Subjects with Hepatitis C Genotype 1

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 11

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Pharmasset Announces 91% SVR12 from the Proton Trial in Subjects with Hepatitis

C Genotype 1

From the PharmaLive.com News Archive - Sep. 06, 2011

Pharmasset, Inc., announced today sustained virologic response (SVR) results

from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in

combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects

with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...